Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 9/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | CCR1 | P32246 | 2/20 | 0.50 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10028305 | 0.85 | OPRL1 (0.46) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL18282707 | 0.83 | OPRL1 (0.55) | OPRL1OPRM1OPRK1OPRD1DRD2 | |
| SCHEMBL24397903 | 0.82 | OPRL1 (0.46) | OPRL1OPRM1OPRK1OPRD1DRD2 | |
| SCHEMBL10057649 | 0.82 | OPRL1 (0.60) | OPRL1OPRM1OPRK1OPRD1DRD2 | |
| SCHEMBL10079145 | 0.81 | OPRL1 (0.64) | OPRL1OPRM1OPRK1OPRD1DRD2 | |
| SCHEMBL3785944 | 0.80 | OPRM1 (0.55) | OPRL1OPRM1OPRK1OPRD1DRD2 | |
| SCHEMBL22605857 | 0.80 | OPRL1 (0.65) | OPRL1OPRM1OPRK1OPRD1DRD2 | |
| SCHEMBL29588372 | 0.80 | SLC6A3 (0.53) | OPRL1OPRM1OPRK1OPRD1DRD2 | |
| SCHEMBL24394078 | 0.80 | OPRL1 (0.53) | OPRL1OPRM1OPRK1OPRD1DRD2 | |
| SCHEMBL23577913 | 0.79 | OPRL1 (0.53) | OPRL1OPRM1OPRK1OPRD1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | MAZE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| WO-2021130723-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LIMITED (IN) | 2021-07-01 | — | — | WO | disclosed |
| US-8148404-B2 | Modulators of CB1 receptors | 7TM PHARMA A/S (DK) | 2012-04-03 | — | — | US | disclosed |
| US-20100144701-A1 | Modulators of CB1 Receptors | 7TM PHARMA A/S (DK) | 2010-06-10 | — | — | US | disclosed |
| US-4954511-A | ALLEVIATING PAIN, TREATING DEPRESSION, CONVULSIONS AND HYPERTENSION | HOECHST-ROUSSELL PHARMACEUTICALS INC. (US) | 1990-09-04 | — | — | US | disclosed |
| US-4914204-A | ANALGESICS, ANTIDEPRESSANTS, ANTICONVULSANTS, HYPOTENSIVE AGENTS | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1990-04-03 | — | — | US | disclosed |
| EP-0333027-A1 | 4-Pentafluorophenoxypiperidines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1989-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | APOL1, APOB, LDLR | OPRL1 108/4885OPRM1 1017/4885OPRK1 912/4885 |
| US-20100144701-A1 | Modulators of CB1 Receptors | CNR1, CNR2, GPR6 | OPRL1 23/4885OPRM1 81/4885OPRK1 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.